top of page
Medical Checkup

EXHALE-2

Trial Enrolment Status

OPEN

Disease Under Study

ASTHMA

Duration

~52 Weeks

About the Trial

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2)

Mechanism of Action:

Dr. George Philteos

Principal Investigator

Dr. George Philteos

Sub-Investigator

Dr. Anushya Chelvanathan

Study Coordinator

Carrie Harrison/Hannah Harrison

bottom of page